Objective To assess trends in the susceptibility to b-lactam agents and to fluoroquinolones of clinically relevant Enterobacteriaceae isolated over a 3-year period in 14 French hospital laboratories.
I N T R O D U C T I O N
In France, b-lactam agents and fluoroquinolones are the antibiotics most frequently prescribed for treating Enterobacteriaceae infections. The clinical importance of Enterobacteriaceae with the potential to acquire resistance to b-lactams related to inhibitor-resistant b-lactamases, extended-spectrum b-lactamases (ESBLs) or stably derepressed cephalosporinases was demonstrated by previous resistance surveys in France [1] [2] [3] [4] . Resistance to fluoroquinolones has recently been shown to be increasing among Enterobacteriaceae in Europe, particularly in Spain [5] [6] [7] . This multicenter study was carried out in 14 French hospital laboratories during a 3-year period, in order to assess the in vitro susceptibility of clinically relevant Enterobacteriaceae isolates to b-lactam agents and to fluoroquinolones.
M A T E R I A L S A N D M E T H O D S

Participating centers
The survey was conducted in 14 French hospitals, seven of 29 metropolitan university hospitals and seven non-teaching hospitals, in 11 different regions, including Ile-de-France (Paris region).
Clinical isolates
During the second quarter of 1996, 1997 and 1998, the participating hospital laboratories each collected the first 180 non-duplicate isolates obtained from clinically significant specimens, according to the reference procedures from the French Society of Microbiology [8] . Isolates from superficial wounds, from ear, nose and throat and from swab samples were excluded.
Susceptibility testing
The disk diffusion method on Mueller-Hinton agar (Sanofi Diagnostics Pasteur, Marnes-la-Coquette, France) was performed in each center according to the recommendations of the Antibiogram Committee of the French Society for Microbiology [9] . ESBLs were detected by the doubledisk synergy test, demonstrating a synergistic effect between co-amoxiclav or ticarcillin þ clavulanic acid and either cefotaxime, ceftazidime or aztreonam [10] . Cefpirome and cefepime were also used to detect ESBLs among cephalosporinasehyperproducing isolates, as previously described [11] . Escherichia coli ATCC 25922 and Escherichia coli C600/pCFF04 (TEM-3) were used as quality controls once a week.
Twenty antibiotics were tested (the zone diameter breakpoints in mm are indicated in parentheses): amoxicillin , co-amoxiclav , ticarcillin , ticarcillin þ clavulanic acid , piperacillin , piperacillin þ tazobactam , cephalothin , cefoxitin , moxalactam , cefotaxime , ceftazidime , aztreonam , cefpirome , cefepime , cefpodoxime , imipenem , nalidixic acid , ofloxacin , pefloxacin and ciprofloxacin . Bacterial strains were classified as susceptible, intermediate and resistant. Isolates showing a positive double-disk synergy test were classified as nonsusceptible to all third-generation cephalosporins and aztreonam, whatever the size of the inhibition zone diameter.
Statistical analysis
The variation in the susceptibility rate over the 3-year period was analyzed by asymptotic chisquare test for trend or by an exact trend test when the number of resistant isolates was particularly small. Regarding the risk of false-positive results due to multiple statistic tests, it can be assumed, from Benjamini et al. [12] , that the nominal alpha risk of 0.05 to define significant differences would lead in this analysis to a high risk of false-positive results (1/3), whereas the P-value of 0.003 would provide a lower risk of false positivity (1/8). Nevertheless, tests with P-values between 0.003 and 0.05 will be presented in the results.
R E S U L T S Distribution of clinical isolates
Of the 7325 isolates collected during the 3-year study period, 88.9% were from adult wards and 10.1% from pediatric wards (data not available in 1%). In total, 6248 (85.3%) isolates were obtained from patients hospitalized in a medical ward (43.1%), surgical ward (19.8%), intensive care units (ICUs) (13.3%) and geriatrics ward (10.4%), and 1049 (14.3%) from emergency wards and outpatients (0.4% not available). Among the 7325 isolates, 70% were recovered from urine, 7.8% from respiratory tract samples, 8.1% from blood, 10.6% from abscesses and drainage fluids, and 3.4% from other clinical specimens.
The overall distribution of bacterial species was as follows: Klebsiella spp. (13.4%) were higher than in other wards. E. coli was the most frequent Enterobacteriaceae isolate in urine (72.3%), blood (68.9%), abscesses (48.3%) and respiratory tract samples (24.6%). P. mirabilis was the second most common isolate (8.4%) encountered in clinical specimens, more often from respiratory tract (11.5%), abscesses (9.9%) and urine (8.4%), and more often in geriatric wards (13.9%) than in other wards.
Cephalosporinase-producing species, including Enterobacter spp., Serratia spp., indole-positive Proteus, Morganella spp. and Providencia spp., represented 30.7% of the isolates in ICUs. This bacterial group represented 46.6% of the isolates from respiratory tract samples and 29.2% of those from abscesses and serous effusions.
In vitro susceptibility to antibiotics
The susceptibility of the Enterobacteriaceae isolates to b-lactams and to fluoroquinolones in 1998 is shown in Table 1 and Table 2 .
For all Enterobacteriaceae isolates, imipenem, extended-spectrum cephalosporins and aztreonam were the most active b-lactam agents, followed by piperacillin þ tazobactam. Fluoroquinolones exhibited good in vitro activity, except for E. aerogenes and Providencia stuartii isolates, for which the susceptibility rates were less than 50%.
The susceptibility rates of the predominant species, Escherichia coli, to amoxicillin, co-amoxiclav, cefotaxime, nalidixic acid, ofloxacin and ciprofloxacin, according to clinical specimens and wards, are shown in Table 3 .
Although no significant change was observed in the susceptibility rates to b-lactams and quinolones among the Enterobacteriaceae overall, speciesto-species analysis revealed individual variation during the 3-year study period.
For E. coli, susceptibility to cephalothin increased from 62.9% to 68.7% (P < 0.001). Among quinolones, the susceptibility of E. coli isolates to ciprofloxacin seemed to decrease (P ¼ 0.04) from 97.2% to 95%.
For P. mirabilis isolates, a slight decrease in susceptibility (P 0.05) to cefotaxime (P ¼ 0.03) and aztreonam (P ¼ 0.04) was observed.
For K. pneumoniae, we observed a >8% increase of the susceptibility rate to extended-spectrum cephalosporins and to aztreonam (P 0.05), and, at the same time, a significant decrease Table 4 ). The susceptibility of K. pneumoniae isolates to pefloxacin (66% versus 81.9%), ofloxacin (68.7% versus 84.1%), nalidixic acid (65.3% versus 76.8%, P ¼ 0.03) and ciprofloxacin (80.3% versus 88.4%) increased.
For cephalosporinase-producing species, the susceptibility to ticarcillin (51.3-58.9%, P ¼ 0.04) and to quinolones (nalidixic acid, pefloxacin and ofloxacin, P ¼ 0.01-0.04) increased. ESBL-producing isolates increased by more than 20% (P ¼ 0.01) over the 3-year period in E. aerogenes ( Table 4 ).
The distribution of ESBL-producing K. pneumoniae and E. aerogenes isolates according to specimens and wards is shown in Table 5 . These isolates were recovered mainly from urine, 
D I S C U S S I O N
The data collected in the microbiological laboratories of 14 hospitals during this 3-year survey update the distribution and the susceptibility pattern to b-lactams and quinolones of Enterobacteriaceae isolates responsible for infections in French hospitals.
It should be noted that one isolate of the same species per patient was considered as a non-duplicate strain instead of one per specimen, as recommended by the ONERBA (Observatoire National de l'Epidémiologie de la Résistance aux Antibiotiques) [13] . Thus, some isolates are missing in the sub-analysis of the results according to clinical specimens. However, this did not significantly alter the results, since the total number of isolates was large.
E. coli represented 64.3% of the total isolates and, as in previous studies, it was the predominant pathogen in urine samples [1, 2, 14] .
Cefotaxime, ceftazidime, cefpirome, cefepime, aztreonam and imipenem had the best overall activity among the b-lactams tested against Enterobacteriaceae.
During the 3-year period, the overall rate of susceptibility to b-lactam agents and fluoroquino-lones remained unchanged. However, some variations in the percentage of susceptible strains were observed at the species level.
More than 99% of E. coli isolates remain susceptible to cefotaxime. The frequency of E. coli isolates producing an ESBL was 0.12-0.5%, while the ceftazidime resistance rate was 1.2-1.6%. This discrepancy can be related to isolates overproducing a cephalosporinase, as confirmed by the 1% of E. coli isolates with full resistance to cefoxitin (data not shown).
This high rate of susceptibility Escherichia coli to third-generation cephalosporins and aztreonam contrasted with the 76.7% susceptibility to coamoxiclav. This is in accordance with other multicenter studies conducted in France between 1988 and 1993 [1, 2, 15, 16] . However, the coamoxiclav susceptibility among E. coli isolates was reported to be variable in French hospitals from different regions [14, 17, 18] . In our study, the lowest frequency of co-amoxiclav-susceptible E. coli (58.7%) was observed in respiratory tract samples.
The rates of susceptibility to fluoroquinolones of Escherichia coli isolates were 96.6%, 94% and 91.3% to ciprofloxacin, ofloxacin and pefloxacin, respectively, as described by other authors [18] . Nevertheless, a slight decrease (1.4%, P ¼ 0.04) in susceptibility to ciprofloxacin was noted.
Six per cent of the total Enterobacteriaceae isolates were intermediate or resistant to cefotaxime, corresponding to isolates producing a chromosomal cephalosporinase and to those producing an ESBL. Ten years after the study of Sirot et al. [1] , this incidence increased from 5.2% to 6%. Comparing these results with those of other studies conducted in Europe is difficult because of methodological differences in susceptibility testing and breakpoint criteria. However, previous reports devoted to antibiotic resistance in Gramnegative bacilli have shown similar activity of blactam agents against Enterobacteriaceae [19, 20] .
One of the most important trends revealed by this study is the increasing susceptibility of K. pneumoniae to third-generation cephalosporins and aztreonam, related to the decrease of ESBLproducing isolates, probably as a consequence of epidemic control measures instituted in hospitals [21] . Thabaut et al. [15] , in a multicenter study including 17 hospitals, noted that the frequency of K. pneumoniae strains resistant to ceftazidime and cefotaxime, after peaking at 24% in 1991, fell to 18% in 1993. In our study, the percentage of K. pneumoniae isolates producing an ESBL decreased from 17.7% to 9.4%. Conversely, European surveys in ICUs in 1994 and in 1997-98 demonstrated that the prevalence of ESBL among Klebsiella was about 25% and remained unchanged [22, 23] .
At the same time, an increase of susceptibility to fluoroquinolones was observed in K. pneumoniae, particularly to ofloxacin and pefloxacin. Contrary to the results published by Brisse et al. [24] , we observed that the increase in susceptibility to fluoroquinolones was linked to the increase in susceptibility to third-generation cephalosporins.
Another outstanding feature is the >20% increase in ESBL-producing strains of E. aerogenes, leading to a dramatic decrease in susceptibility rates (<50%) to third-generation cephalosporins and aztreonam. As shown by Bosi et al. [25] , this can be explained by the spread in French hospitals of ESBL-producing strains of E. aerogenes belonging to a prevalent clone.
For K. oxytoca, a positive double-disk synergy test may indicate an ESBL or overproduced chromosomal OXY-type b-lactamase [11] . Thus, susceptibility to third-generation cephalosporins may have been underestimated, since these isolates were never considered as susceptible to these antibiotics [9] . In our study, ESBLs were found in only three isolates of K. oxytoca (data not shown). Without any interpretation, the overall rate of susceptibility over the 3 years was 96% to cefotaxime, 97% to ceftazidime, 94.6% to cefpirome, 98% to cefepime and 83% to aztreonam.
In conclusion, after many years of use in French hospitals, third-generation cephalosporins and fluoroquinolones retain good in vitro activity against the most frequent isolates of the family Enterobacteriaceae, except E. aerogenes. Further studies are needed to understand why this species is currently the predominant ESBL-producing Enterobacteriaceae species in France.
